Objective-The flow-responsive Kruppel-like factor 2 (KLF2) is crucial for maintaining endothelial cell quiescence. Here, we describe its detailed effects on transforming growth factor-␤ (TGF-␤) signaling, which normally has proatherogenic effects on endothelium. Methods and Results-In-depth analysis of genome-wide expression data shows that prolonged lentiviral-mediated overexpression of KLF2 in human umbilical vein endothelial cells (HUVECs) diminishes the expression of a large panel of established TGF-␤-inducible genes. Both baseline and TGF-␤-induced expression levels of plasminogen activator inhibitor 1 (PAI-1) and thrombospondin-1 are greatly diminished by KLF2. Using a combination of ectopic expression, small interfering RNA-mediated knockdown, and promoter activity assays, we show that KLF2 partly inhibits the phosphorylation and subsequent nuclear accumulation of Smad2, thereby suppressing the TGF-␤-induced Smad4mediated transcriptional activity. This is achieved through TGF-␤-independent induction of inhibitory Smad7. Additionally, a full inhibition of TGF-␤ signaling is functionally achieved through a simultaneous suppression of activator protein 1 (AP-1), which is an essential cofactor for TGF-␤-dependent transcription of many genes.
T he role of TGF-␤ in vascular biology and pathology is still enigmatic, even though it has been the subject of many studies. This is likely because of the complexity of the processes that take place in the vessel wall, involving many cell-types, each of which responds differently to TGF-␤ depending on the specific cellular context. For example, TGF-␤ signaling in macrophages, smooth muscle cells, and T-lymphocytes is deemed atheroprotective, as it was found to be associated with a decrease in inflammation and vulnerable plaque formation in atherosclerosis. [1] [2] [3] TGF-␤ signaling in large vessel endothelium, however, promotes apoptosis and increases permeability through mitogen-activated protein kinase (MAPK) p38. 4, 5 Furthermore, TGF-␤ induces the endothelial oxidized-LDL receptor OLR1, 6 plasminogen activator inhibitor 1 (PAI-1), 7 and monocyte chemotactic protein 1 (MCP-1), 8 all of which are considered proatherogenic. A more detailed understanding of the mechanisms that can control the various aspects of TGF-␤ signaling in endothelium are thus of great interest for understanding a variety of vascular processes including atherosclerosis.
TGF-␤ signaling occurs through a heteromeric complex of type I and type II TGF-␤ receptors. 9 Endothelial cells express one type II receptor and two type I receptors, activin receptor-like kinase (ALK) 5 and ALK1. Stimulation with TGF-␤ results in phosphorylation of either ALK1, which leads to phosphorylation of receptor-regulated Smads (R-Smads) Smad1 and Smad5, or ALK5, which leads to phosphorylation of R-Smads Smad2 and Smad3. Phosphorylated R-Smads subsequently translocate to the nucleus with Smad4, where gene expression is regulated through binding to Smad binding elements. Parallel to signaling through Smad proteins, TGF-␤ signaling has also been described to occur through MAPKs, probably synergistically with Smad signaling. 10 MAPKs like Jun N-terminal kinase (JNK) and p38 act through activation of activator protein 1 (AP-1), which consists of a homo-or heterodimer of members of the Jun, Fos, musculoaponeurotic fibrosarcoma oncogene homolog (MAF), or activated transcription factor (ATF) families. 11 Known attenuators of TGF-␤ signaling are the inhibitory Smads (I-Smads) Smad6 and Smad7, which compete with R-Smads for association with the type I TGF-␤ receptor, thereby inhibiting phosphorylation of R-Smads. Moreover, Smad7 induces degradation of the type I receptor by recruit-ing ubiquitinases. 12 Interestingly, Smad7 is a TGF-␤ target gene itself, thus contributing to a negative feedback loop in TGF-␤ signaling. Inhibitory Smad7 is known to be endothelial specific and to be induced in vivo by shear stress. 13, 14 We have previously identified the transcription factor Kruppel-like factor 2 (KLF2) to be exclusively expressed by endothelial cells exposed to high shear stress. 15 Furthermore, we recently showed that KLF2 affects the expression of vascular tone-regulating genes 16 and establishes a differentiated quiescent endothelial gene expression pattern. 17 Endothelial KLF2 was also shown to inhibit proinflammatory response, 18, 19 to suppress prothrombotic function, 20 and to attenuate angiogenesis. 21 Mice lacking KLF2 die in utero because of severe vascular malformations, caused by the inability of endothelial cells to properly organize smooth muscle cells in the vessel wall, resulting in hemorrhage. 22 Here, we report that KLF2 robustly inhibits TGF-␤ signaling in endothelial cells by abrogating the phosphorylation of Smad2 in cultured cells and in vivo, and suppressing both Smad3/4-and AP-1-mediated activation of TGF-␤ inducible promoters. Using a combination of lentiviral overexpression and small interfering RNA-mediated knockdown, we provide evidence that the inhibition of TGF-␤ signaling by KLF2 is mediated through the induction of Smad7 and through the suppression of the active AP-1 component c-Jun.
Methods
A detailed description of the methods is available in the supplemental materials at http://atvb.ahajournals.org.
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated and cultured as previously described. 23 Confluent monolayers were grown from freshly isolated HUVECs and used before the fourth passage.
Lentiviral Overexpression, Western Blotting, and Microscopy
Long-term lentiviral overexpression of KLF2, microscopy, and Western blotting were performed as previously described. 17
Immunohistochemistry and Immunofluorescence
Immunohistochemistry and immunofluorescence was performed essentially as described. 16, 17 
Luciferase Reporter Constructs and Assay
Firefly luciferase reporter constructs and a GAPDH-Renilla luciferase control construct were transfected into HUVECs by electroporation using the nucleofector system (Amaxa). Luciferase activity was measured with the dual luciferase reporter assay system following the manufacturer's protocol (Promega).
RNA Silencing by Double-Stranded RNA Oligonucleotides
Double-stranded siRNA oligonucleotides were synthesized by Ambion. Oligofectamine (Invitrogen) was used as transfection agent for introduction of the siRNA oligonucleotides into HUVECs, according to the manufacturer's instructions.
Real-Time RT-PCR
Real-time RT-PCR was performed as described. 16 
Results

KLF2 Abrogates TGF-␤-Induced Gene Expression
Recently, we described the initial analysis and validation of a genome-wide microarray expression profiling study into the general effects of prolonged lentivirus-mediated overexpression of human KLF2 at physiological levels in human umbilical vein endothelial cells (HUVECs). 17 We now performed an in-depth analysis of these expression data probing for affected canonical (signaling) pathways, using the recently published Gene Set Enrichment Analysis (GSEA). 24 One of the highest ranking canonical pathways affected by KLF2 is TGF-␤ signaling, which is substantially suppressed (nominal probability value 0.023). Based on the initial default analysis, a custom gene set for endothelial cell TGF-␤ targets was constructed containing the core-enriched signaling and downstream effector genes. Figure 1A shows an overview of the TGF-␤ signaling cascade and the core-enriched downstream targets from the GSEA, with superimposed the expression ratio data showing KLF2-upregulated (red) and KLF2-downregulated genes (green). The numbers in the figure indicate fold change in microarray intensity signals of mRNA from KLF2-transduced cells compared with mocktransduced HUVECs. Validation of the KLF2-suppressed basal expression of most of the archetypal TGF-␤ downstream genes depicted, most notably: MCP-1, PAI-1, and THBS1 were presented previously. 17 To investigate the mechanism by which KLF2 represses TGF-␤ target gene expression, we studied the expression of THBS1 and PAI-1. These genes are known to be induced by TGF-␤, are highly expressed in endothelium, are robustly downregulated by KLF2, and are considered to be proatherogenic. 7, 25, 26 On stimulation of HUVECs with TGF-␤, mRNA levels of THBS1 and PAI-1 increased approximately 5-and 10-fold, respectively, as measured by RT-PCR ( Figure 1B and 1C). In KLF2-overexpressing HUVECs, not only the basal expression levels of THBS1 and PAI-1 were significantly lower but also their induction by TGF-␤ is severely blunted. These data illustrate that KLF2 suppresses the expression of THBS1 and PAI-1 both in the absence and the presence of exogenous TGF-␤, which suggests that the attenuation of TGF-␤ signaling by KLF2 occurs at the receptor level or downstream thereof, and not by altered levels of secreted biologically active TGF-␤ isoforms.
KLF2 Increases Smad7 Independent of ALK5-Mediated TGF-␤ Signaling
Next, we studied the expression of various genes known to be involved in the regulation of TGF-beta signaling through Smad-proteins by RT-PCR ( Figure 2A ). The expression of 4 of the examined genes is significantly affected by KLF2. TGF-␤1 is 2-fold downregulated, TGF-␤2 is 4-fold downregulated, and the I-Smads Smad6 and Smad7 are upregulated 4-and 3-fold, respectively. Smad7 was reported to be induced in vivo by shear stress, 13 as is KLF2. 16 Long-term laminar shear stress induces Smad7 levels in our cultured endothelial cells to the same levels as observed when overexpressing physiological levels of lentiviral encoded KLF2 ( Figure 2B and supplemental materials). As Smad7 promoter activity is induced by TGF-␤, the inhibitory Smad7 normally acts as a negative feedback on this signaling cascade. 14 The KLF2-mediated induction of Smad7, however, is independent of ALK5-mediated TGF-␤ signaling, as shown by the results in the presence of the specific receptor-blocker SB431542 with both mock-and KLF2-transduced HUVEC ( Figure 2B ). KLF2 induction of Smad7 is confirmed at the protein level by Western blot analysis ( Figure 2C ).
Cytoplasmic localization of Smad7 is required for inhibition of phosphorylation of Smad2, which occurs near the plasma membrane, whereas nuclear localized Smad7 was shown to be inactive. 12 Figure 2D shows immunofluores- Figure 1 . KLF2 represses TGF-␤ target gene expression. A, Microarray expression profiling intensity ratios of KLF2versus mock-transduced HUVECs 17 are superimposed on a customized scheme of the TGF-␤ signaling cascade, generated with GenMAPP2.0 to include the downstream genes that were found to be significantly downregulated by KLF2 using Gene Set Enrichment Analysis. 24 Depicted are genes induced (red) or suppressed (green) by KLF2 (absolute ratio Ͼ1.3-fold and False Discovery Ratio (FDR) probability value Ͻ0.001), whereas genes of equal expression are visualized in yellow (when expressed in HUVECs) (absolute ratio Ͻ1.3-fold or FDR probability value Ͼ0.001) or gray (no reliable intensity data). Numbers indicate fold change in signal intensities in KLF2compared with mock-transduced HUVECs. B and C, HUVECs transduced with mock-or KLF2-lentivirus were stimulated with TGF-␤3 for 2 or 24 hours or left unstimulated. RNA levels for PAI-1 and THBS1 were analyzed by real-time RT-PCR (nϭ3). *PϽ0.05. cence microscopy images of HUVECs with Smad7 protein in red and nuclear staining in blue. Overexpression of KLF2 is shown to increase active cytoplasmic and plasma membrane localized Smad7 protein, but also to a lesser degree, inactive nuclear localized Smad7. Also visible is the smaller size of KLF2-transduced cells, as we described previously. 17 Taken together, these experiments signify that KLF2 augments active Smad7 protein, independent of TGF-␤ signaling.
KLF2-Induced Smad7 Suppresses Smad2 Phosphorylation and Smad3/4-Dependent Transcriptional Activation
To determine whether KLF2-induced Smad7 inhibits TGF-␤ signaling by inhibiting phosphorylation of R-Smads, we used specific antibodies raised against phosphorylated Smad2 (P-Smad2) and Smad3 (P-Smad3). Western blot analysis revealed that KLF2-transduced HUVECs contain lower levels of P-Smad2 and P-Smad3 compared with mocktransduced cells, whereas total Smad2 levels are unaltered ( Figure 3A and supplemental materials) . Also, TGF-␤ stimulation induces phosphorylation in mock-transduced HUVECs but not in KLF2-transduced cells. On phosphorylation, Smad2 typically translocates to the nucleus to influence transcriptional activity. Immunofluorescence analysis confirmed that P-Smad2 is indeed located predominantly in the nucleus in both mock-and KLF2-transduced cells, but is lower in KLF2-transduced cells ( Figure 3B and supplemental materials). These results indicate that KLF2 inhibits the TGF-␤ signaling pathway in HUVECs upstream of the phosphorylation of Smad2, leading to lower levels of active P-Smad2 in the nucleus.
Next, we used an established Smad3/4-binding and TGF-␤-responsive promoter element 27 to elucidate whether the observed abrogating effect of KLF2 on phosphorylation of R-Smads leads to actual transcriptional suppression. This artificial (CAGA) 12 luciferase reporter is known to be activated only by Smad3/4 binding and can thus be used to specifically determine Smad3/4-mediated TGF-␤ signaling. Mock-and KLF2-transduced HUVECs were transfected by electroporation with the (CAGA) 12 luciferase reporter and subsequently treated with the ALK5 inhibitor SB431542, to minimize residual autocrine TGF-␤ activity, or with TGF-␤ for 16 hours before measuring luciferase activity ( Figure 3C ). As expected, stimulation with TGF-␤ greatly induces reporter activity to approximately 18-fold in mock-transduced cells, when compared with SB431542-treated cells. In contrast, reporter activity in TGF-␤-treated KLF2-transduced cells increases only 5-fold compared with SB431542-treated KLF2-transduced cells. This implies that KLF2 inhibits TGF-␤ signaling in HUVECs partially by specifically diminishing Smad3/4 transcriptional activity.
To determine whether the decrease in phosphorylation of Smad2 by KLF2 is mediated by Smad7, mock-and KLF2transduced HUVECs were transfected with either double- Figure 3 . KLF2 inhibits phosphorylation of Smad2 in a Smad7-dependent manner and suppresses Smad3/4-mediated transcription. A, Western blot analysis was performed with total cell lysates of mock-and KLF2-transduced HUVECs that were treated with 10 ng/mL TGF-␤3 or vehicle for 16 hours. Blots were probed with antibodies raised against P-Smad2 and with antibodies against ␣ -tubulin. The bar graph indicates quantified levels of P-Smad2 corrected for ␣ -tubulin. B, Immunofluorescence images of HUVECs after stimulation with 10 ng/mL TGF-␤3 for 16 hours. P-Smad2 is visualized in red, Hoechst nuclear staining in blue. Bars indicate 10 m. C, Cells were transfected by electroporation with luciferase reporter constructs containing the Smad3/4 specific (CAGA) 12 -artificial promoter (nϭ3). Luciferase activity was measured 16 hours after addition of 10 mol/L ALK5 inhibitor SB431542 or 10 ng/mL TGF-␤3. D, Western blot analysis was performed with total cell lysates of mock-and KLF2-transduced HUVEC, 24 hours after transfection with doublestranded RNA oligonucleotides designed either to specifically silence Smad7 (siSmad7) or to be nonspecific. Blots were probed with P-Smad2 or ␣ -tubulin antibodies. The bar graph illustrates quantified levels of P-Smad2 corrected for ␣-tubulin (nϭ3). *PϽ0.05, **PϽ0.01, ***PϽ0.0005. stranded RNA oligonucleotides to specifically silence Smad7 (siSmad7) or with nonspecific control oligonucleotides (Figure 3D ). Introduction of siSmad7 reduces Smad7 mRNA in KLF2-transduced cells to about the same levels observed in cells transfected with control oligonucleotides (see supplemental materials). This reduction of Smad7 is sufficient to restore phosphorylation of Smad2 in KLF2-transduced cells to approximately the levels observed in mock-transduced endothelial cells ( Figure 3D) . These data suggest that KLF2 inhibits the TGF-␤ signaling cascade by decreasing phosphorylation of Smad2 through induction of Smad7.
Endothelial P-Smad2 Levels Are Diminished In Vivo in Atheroprotected Arterial Regions
We examined sections of a mouse carotid artery collar model 16 and human arteries using immmunohistochemical techniques, to assess whether P-Smad2 levels are also diminished in vivo in endothelium that expresses increased levels of KLF2 (Figure 4 and supplemental materials) . Mouse carotid artery sections and human donor arterial tissue, displaying either an early focal "fatty-streak" or a more advanced acentric lesion, which tend to develop at the low shear stress side of the artery, 16 were stained for KLF2, P-Smad2, HAM56, and CD31. Endothelial cells overlying lesions display diminished levels of KLF2 and enhanced P-Smad2 levels compared with healthy endothelium from the same section. Collectively, these data suggest that high endothelial expression of KLF2 provoked by shear stress is inversely correlated to phosphorylation of Smad2 in vivo.
KLF2 Decreases c-Jun Transcriptional Activity on a TGF-␤-Responsive Promoter
An apparent discrepancy is revealed when comparing the partial Smad-dependent effects of KLF2 on an artificial (CAGA) 12 -promoter ( Figure 3C ) to its complete inhibitory effect on endogenous gene expression ( Figure 1 ). Therefore, we studied its effects on an established TGF-␤-responsive core promoter, originally derived from the murine Smad7 gene. This core-promoter fragment contains a synergistic module composed of both a Smad3/4 binding site and an AP-1 binding site, as is frequently observed in TGF-␤responsive genes. 28 Luciferase activity was measured for the wild-type reporter or reporter constructs containing mutations in either the AP-1 binding site or the Smad binding element (SBE) after incubation with TGF-␤ or SB431542 for 16 hours. The activity of the TGF-␤ responsive part of the wild-type reporter was indeed induced by TGF-␤ in mocktransduced cells compared with SB431542 treatment ( Figure  5A ). In contrast, induction of luciferase activity after TGF-␤ stimulation in KLF2-transduced HUVECs is completely abrogated. Notably, baseline levels are similar to mocktransduced cells, indicating that there is no direct effect of KLF2 on the expression of this Smad7 core-promoter. Mutation of the SBE leads to a marked drop in transcriptional activity and loss of TGF-␤ responsiveness in both mock-and KLF2-transduced HUVECs, confirming that Smad3/4 binding is essential for both baseline and TGF-␤-induced transcriptional activity ( Figure 5A) .
Mutation of the AP-1 binding site equally results in a loss of TGF-␤ responsiveness of this core-promoter, confirming the crucial role of AP-1 in Smad-driven transcription. Interestingly, we also noted a significantly decreased basal tran-scriptional activity of the AP-1 site containing, SBE-mutated construct in the KLF2-transduced cells. We therefore analyzed the levels of active AP-1 in KLF2-and mocktransduced cells. c-Jun is a main component of AP-1, but to be active it needs to be localized in the nucleus in a phosphorylated form (P-c-Jun). 11 This was directly assessed by transcription factor analysis of nuclear extracts, which shows that KLF2 indeed reduces the levels of active nuclear localized P-c-Jun by 80% ( Figure 5B ). In addition, P-c-Jun localization was analyzed by immunofluorescence, showing that KLF2 suppresses both the nuclear-localized amount and the total intracellular amount of P-c-Jun ( Figure 5C ). In marked contrast, total c-Jun protein levels are unaffected by KLF2 ( Figure 5D ), indicating that KLF2 inhibits the phosphorylation, rather than the expression levels of c-Jun.
Discussion
The present study provides evidence that endothelial KLF2 attenuates transcription of many TGF-␤ target genes, including PAI-1 and THBS1 ( Figure 1B and 1C) and completely abrogates transcriptional activity on endogenous TGF-␤inducible promoter fragments ( Figure 5A ). This is shown to be partially achieved by the induction of Smad7 (Figure 2) , which subsequently suppresses the phosphorylation of Smad2 (Figure 3A and 3D) and inhibits transcriptional activity of Smad3/4 ( Figure 3C ). Synergistically, KLF2 inhibits the phosphorylation and thus activation of the essential cofactor for TGF-␤ signaling AP-1 ( Figure 5 ). These findings are supported by the observation that P-Smad2 levels are indeed higher in vivo at sites of the vasculature that correlate with suppressed endothelial KLF2 levels (Figure 4 ).
Smad7 has been described to be specifically expressed in endothelium and to be induced by both shear stress and TGF-␤. 13, 14 KLF2 is also exclusively expressed by endothelial cells exposed to high shear stress. 15 Because we describe that KLF2 inhibits TGF-␤-dependent transcription, this should lead to a decrease in Smad7 transcription. Here it is shown, however, that KLF2 induces Smad7 independent of ALK5-mediated TGF-␤ signaling ( Figure 2B ). KLF2 indeed does not induce the expression of Smad7 through the TGF-␤-responsive part of its promoter in the presence or absence of the ALK5 inhibitor SB431542 ( Figure 5A ). Therefore, KLF2 must act either directly or indirectly via one of its many downstream genes, on a different part of the Smad7 promoter or intergenic regions. Unfortunately, neither a specific consensus binding sequence for KLF2 nor for any of its KLF family members has been defined, except for the core binding sequence (CACCC), 29 which is ubiquitously present in the human genome making it at present difficult to pinpoint a specific putative KLF2 binding site in the Smad7 promoter.
We show that induction of Smad7 is responsible for the suppression of P-Smad2 by KLF2. However, P-Smad2 is not completely absent in KLF2-transduced cells (Figure 3A, 3B , and 3E), and this could explain the relatively mild reduction in Smad3/4-dependent transcription ( Figure 3C ). On the contrary, a complete inhibition on target gene expression ( Figure 1B and 1C ) and the full abrogation of TGF-␤ responsiveness on the endogenous TGF-␤-responsive promoter piece of Smad7 ( Figure 5A ) by KLF2 were observed. Figure 5 . KLF2 inhibits AP-1 activity and promoter response. A, Luciferase reporter constructs containing either the wild-type TGF-beta responsive part (Ϫ613 to ϩ112) of the murine Smad7 promoter or the same part with mutations in either the Smad binding element (SBE mut) or the AP-1 binding element (AP1 mut) were used as a measure for physiological TGF-beta signaling. 28 Luciferase activity was measured 16 hours after addition of 10 mol/L ALK5 inhibitor SB431542 or 10 ng/mL TGF-␤3 to either mock-or KLF2-transduced HUVEC (nϭ4). B, Using a transcription factor ELISA, DNA binding activity of nuclear localized P-c-Jun was measured in mock-and KLF2-transduced HUVECs A plausible explanation for this observation is that endogenous TGF-␤-induced gene expression requires not only Smad3/4, but also its cofactor AP-1. 28 In support of this explanation, we show that KLF2 diminishes AP-1 activity ( Figure 5B ) and that mutation of the SBE alone in the Smad7-derived promoter fragment does not abolish decreased transcriptional activity in KLF2-transduced cells compared with control cells ( Figure 5A ). Indeed, promoters of 3 of the most downregulated genes in KLF2-transduced cells, Endothelin-1, MCP-1, and PAI-1 ( Figure 1A ) have all been shown to contain both essential Smad3/4 and AP-1 binding sites. 27, 30, 31 Because active P-c-Jun is reduced by KLF2, but total c-Jun protein levels are unaffected by KLF2 ( Figure 5D ), it is likely that KLF2 directly or indirectly inhibits JNK to reduce phosphorylation of c-Jun ( Figure 6 ).
Previously, we reported that KLF2 establishes endothelial quiescence by directly and indirectly regulating the expression of over a thousand genes. 17 We now show that KLF2 specifically inhibits TGF-␤ signaling through a novel concerted mechanism involving both Smad7 and AP-1. Thus, one of the mechanisms is established that explains part of the vast indirect transcriptional regulation that constitutes KLF2driven endothelial quiescence. Furthermore, this is shown to directly result in a downregulation of a distinct set of TGF-␤-inducible genes, which are considered proatherogenic 4 -8 and/or profibrotic 32 (Figure 1A) . Collectively, these results suggest that healthy flow-induced KLF2 will contribute directly to a quenching of the pathological role of TGF-␤ in various vascular processes, including atherosclerosis. Figure 6 . KLF2 inhibits TGF-␤ signaling via two distinct routes. KLF2-mediated induction of Smad7 leads to the inhibition of phosphorylation of Smad2, which leads to diminished transcriptional activity of Smad4. To establish full abrogation of TGF-␤ target genes, KLF2 simultaneously inhibits the activation of the TGF-␤ signaling cofactor AP-1.
